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Trends in the national outcomes and costs for
claudication and limb threatening ischemia:
Angioplasty vs bypass graft
Teviah Sachs, MD, MPH, Frank Pomposelli, MD, Allen Hamdan, MD, Mark Wyers, MD, and
Marc Schermerhorn, MD, Harvard, Mass
Purpose: Debate exists as to the benefit of angioplasty vs bypass graft in the treatment of lower extremity peripheral
vascular disease. The associated costs are poorly defined in the literature. We sought to determine national estimates for
the costs, utilization, and outcomes of angioplasty and bypass graft for the treatment of both claudication and limb
threat.
Methods: We searched the Nationwide Inpatient Sample (NIS) database (1999-2007), identifying patients who had an
identifiable International Classification of Disease (ICD)-9 diagnosis code of atherosclerotic disease (claudication
[440.21] or limb threat [440.22-440.24]). Of these, only patients who underwent intervention of angioplasty  stent
(percutaneous transluminal angioplasty [PTA; 39.50-39.90]), peripheral bypass graft (BPG; 39.29) or aortofemoral
bypass (ABF; 39.25) were included. We compared demographics, costs, and comorbidities, as well as multivariable-
adjusted outcomes of in-hospital mortality and major amputation. Additionally, we used the New Jersey State Inpatient
and Ambulatory databases in order to better understand the influence of outpatient procedures on current volume and
trends.
Results: There were 563,143 patients identified (PTA: 38%, BPG: 50%, ABF: 6%; 5.1%: multiple procedure codes).
Patients who had PTA and BPGwere similar in age (70.4 vs 69.5 years) but older than patients who had ABF (61.8 years,
P < .01). Patients who underwent PTA were more often women (PTA: 46%, BPG: 42%, ABF: 45.2%; P < .01). Average
costs for PTA increased over 60% for claudication between 2001 and 2007 ($8670 to $14,084) and limb threat ($13,903
to $23,196). For BPG, average costs increased 36% for both claudication ($9322 to $12,681) and limb threat ($16,795
to $22,910). In 2007, the average cost per procedure of PTA was higher than BPG for both claudication ($13,903 vs
$12,681; P  .02) and limb threat ($23,196 vs $22,910; P  .04). The number of patients per year undergoing PTA
increased threefold (15,903 to 46,138) for claudication and limb threat (6752 to 19,468). For BPG, procedures per year
decreased approximately 40% for both claudication (13,625 to 9108) and limb threat (25,575 to 13,762). In-hospital
mortality was similar for PTA and BPG groups for claudication (0.1% vs 0.2%; P  .04) and limb threat (2.1% vs 2.6%;
P < .01). In-hospital amputation rates were significantly higher for patients who had PTA (7%) than BPG (3.9%, odds
ratio [OR], 1.67 [1.49-1.85]; P < .01) or patients who underwent ABF (3.0%; OR, 2.32 [1.79, 3.03]; P < .01).
Conclusion: PTA has altered the treatment paradigm for lower limb ischemia with an increase in costs and procedures. It
is unclear if this represents an increase in patients or number of treatments per patient. Although mortality is slightly
lower with PTA for all indications, amputation rates for limb-threat patients appear higher, as does the average cost.
Longitudinal studies are necessary to determine the appropriateness of PTA in both claudication and limb-threat
patients. The mortality benefit with PTA may be ultimately lost, and average costs elevated, if multiple interventions are
performed on the same patients. ( J Vasc Surg 2011;54:1021-31.)
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America and Europe carry a diagnosis of peripheral arterial
disease.1 Approximately 4% of adults in theUnited States will
develop claudication by middle age, and as high as 14% after
age 70.2,3 For patients who carry a diagnosis of claudication,
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doi:10.1016/j.jvs.2011.03.281pproximately 20% will have progressive symptoms and 1%
o 2% will develop critical limb ischemia (limb threat)
ithin 5 years.4 While limited medical therapies are avail-
ble for those in whom intervention is contraindicated,5 the
ainstay of treatment for limb threat remains bypass or
ndovascular techniques. Recent evidence has shown sim-
lar outcomes between angioplasty-first and bypass-first
trategies for severe lower extremity ischemia.6,7 With the
onstant advance of endovascular techniques for peripheral
rterial disease (PAD), the number of patients with PAD
ho are treated with those techniques has steadily grown.8
ecent data from the Bypass versus Angioplasty in Severe
schaemia of the Leg (BASIL) trial recommend a bypass-
rst strategy in patients expected to live longer than 2
ears.9 Further confounding the picture are reports that
ropose a comparable, and in some cases superior, benefit
ith exercise as opposed to invasive procedures for claudi-
ation.10-14
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October 20111022 Sachs et alNational estimates of both endovascular and open sur-
gery for PAD can be conflicting, often confounded by the
inclusion of claudication and limb threat.8,15,16 Further-
more, the costs associated with these procedures are not
well defined. We evaluate national trends in utilization and
associated costs, as well as outcomes of in-hospital mortal-
ity and amputation for both open and endovascular tech-
niques stratified by indication for revascularization: claudi-
cation and critical limb ischemia.
METHODS
We used the Nationwide Inpatient Sample (NIS) data-
base which represents a 20% stratified sample of all payer –
insured and uninsured – hospitalizations. The data set
represents approximately eight million hospitalizations per
year. This data can further be weighted to approximate
national estimates. All of our analyses were performed using
weighted data.
We examined all medical records between 1999 and
2007. Using International Classification of Diseases, 9th
edition (ICD-9) diagnosis codes, we selected only those
patients with a diagnosis code of atherosclerotic disease
where disease severity was distinctly identifiable (claudica-
tion: 440.21; rest pain: 440.22; ulcer: 440.23; or gangrene:
440.24), and whose primary admitting diagnosis was re-
lated to atherosclerosis (Appendix). Of these, we selected
only patients who underwent either angioplasty with or
without stent (39.50, 39.90), or bypass graft (aortoiliac-
femoral: 39.25 or peripheral: 39.29). We then compared
cohorts by the presumed indication for intervention, which
was either claudication (440.21) or limb threat (440.22,
440.23, and 440.24). Individual indications of rest pain,
ulcer, and gangrene were also subanalyzed. We further
examined the type of operation, comparing groups of (1)
percutaneous transluminal angioplasty (PTA) with or with-
out stent (PTA S), (2) peripheral bypass graft (BPG), and
(3) aortoiliac-femoral bypass (ABF). Patients who had
codes for more than one procedure were excluded from
comparison analysis. We compared demographics, co-
morbidities, admission and discharge status, and multi-
variable-adjusted outcomes of death and major amputa-
tion, as well as the combined outcome of death or major
amputation. Multivariable logistic regression adjusted
for variables of gender, age, and comorbid conditions of
renal failure, congestive heart failure, diabetes, hyperten-
sion, cardiac valvular disease, and chronic obstructive
pulmonary disease. Total charges and total costs were
evaluated, using cost-to-charge ratios as available from
Healthcare Cost and Utilization Project.17 Cost-to-
charge ratio data are only available beginning in 2001.
We evaluated changes in procedure volume and associ-
ated costs over time. Costs are reported as dollar
amounts per case and include all costs for the hospital-
ization.
Data regarding outpatient procedures are not available in
the NIS database. However, New Jersey is one of the select
few states which make this data available in their State Ambu-
latory SurgeryDatabase (SASD) aswell as their State Inpatient 2atabase (SID). These databases represent 100% samples of
ischarges and ambulatory procedures, respectively, within
he state. In order to estimate the differential costs of ambu-
atory surgery procedures, which were not included in the
IS, we performed a separate analysis using the New Jersey
ASD and SID between the years 2005 and 2007.
We used SAS version 9.2 and SAS Callable SUDAAN
ersion 10 (SAS Institute, Cary, NC) for all statistical analyses.
rends were analyzed using the Cochran-Armitage test
f linear trend, and are reported as a two-sided P value
ith significance .05. The 2 analysis was used for
omparison of categorical variables and t test or Wil-
oxon rank-sum test for continuous variables. Analyses
nvolving more than two groups were performed using a
ultiple comparison test for proportional data18 (signif-
cance: q-statistic q[.05] critical value) and analysis of
ariance with Tukey’s range test for mean data (signifi-
ance level .05).
ESULTS
ationwide inpatient sample
We identified 629,401 patients between 1999 and
007 with a diagnosis of atherosclerosis. Of these patients,
6,258 of them had a diagnosis of “atherosclerosis unspec-
fied” and were excluded from further analysis. The remain-
ng 563,143 patients underwent intervention for well-
efined level of atherosclerotic disease: claudication or limb
hreat. Of these, 218,655 patients (38.8%) underwent an-
ioplasty with or without stent (PTA  S), 280,021 pa-
ients (49.7%) underwent peripheral bypass graft (BPG),
6,307 patients (6.4%) underwent aortofemoral bypass
ABF), with the remaining patients (5.1%) having codes for
oth open and endovascular procedures (Table I).
Demographics and comorbidities. Patients who re-
eived PTA  S were similar in age when compared to
atients who received BPG, and both PTA  S and BPG
roups were older than patients who underwent ABF (me-
ian ages: PTA  S: 70.4 years old; BPG: 69.5 years old;
BF: 61.8 years old; P .01). This difference was seen for
oth claudicants and patients with limb threat (Table II, A
nd B); however, on average, claudicants were younger
han patients with limb threat (67 years old vs 72 years old;
 .01), patients who had PTA were also more often
omen in both claudicants and patients with limb threat.
n both claudicants and patients with limb threat, patients
ho had PTA  S had higher rates of hypertension, renal
ailure, and diabetes than either patients who received BPG
r ABF. They also had lower rates of chronic pulmonary
isease than either patients with BPG or ABF. Patients who
ad PTA  S had lower rates of congestive heart failure
han patients with BPG (12.1% vs 14.3%; P  .01), but
igher rates than found in ABF (12.1% vs 9.5%; P  .01).
here was no significant difference in obesity between the
hree groups.
Procedure volume over time. Between 1999 and
007, procedures for claudication increased by 58%, from
4,488 to 38,785 (test of trend: P .01) while procedures
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w
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Volume 54, Number 4 Sachs et al 1023for limb threat remained relatively stable, increasing only
5% from 34,402 to 36,147 (P  .045) over the same time
period (Fig 1). Interventions for claudication outnumbered
those for limb threat beginning in 2005. PTA  S proce-
dures increased approximately threefold between 1999 and
2007, for both claudication (6416 to 26,671; P .01) and
limb threat (5002 to 19,468; P  .01). BPG operations
decreased in both groups, dropping by a third for claudica-
tion (13,625 to 9108; P .01) and by almost half for limb
Table I. Numbers of patients identified as having atherosc
inpatient sample: 1999-2007
Numbers
Total PTA Per
(n) (%) (n) (%) (
Total 563,143 100.0 218,655 38.8 280
Year (1999) 60,155 100.0 11,725 19.5 40
Year (2000) 58,260 100.0 12,600 21.6 37
Year (2001) 60,876 100.0 16,295 26.8 36
Year (2002) 58,687 100.0 15,889 27.1 35
Year (2003) 54,861 100.0 18,202 33.2 29
Year (2004) 57,783 100.0 23,847 41.3 27
Year (2005) 63,351 100.0 31,479 49.7 25
Year (2006) 73,656 100.0 42,262 57.4 24
Year (2007) 75,514 100.0 46,356 61.4 23
PTA, Percutaneous transluminal angioplasty.
Table II. A, Demographics and comorbidities of patientsa
intervention: 1999-2007
Nationwide Inpatient
Sample (1999-2007)
Total
(n  264,231)
PTA  S
(n  128,937)
Demographics (n) (SD) (n) (SD)
Mean age 67 0.13 69 0.2
(n) (%) (n) (%)
Female gender 104,428 40.1 55,572 43.1
Race 191,830 100.0 97,891 100.0
White 160,596 83.7 80,909 82.7
Black 16,692 8.7 8332 8.5
Other 14,542 7.6 8650 8.8
Comorbidities
CHF 16,978 6.6 8637 6.7
Valvular disease 11,939 4.7 7160 5.6
Hypertension 174,214 68.2 89,974 69.8
Renal failure 11,651 4.6 7795 6.1
Diabetes 68,966 27.0 37,952 29.5
Obesity 9546 3.7 4491 3.5
Chronic pulmonary disease 56,041 21.9 22,015 17.1
ABF, Aortofemoral bypass; CHF, congestive heart failure; ICD-9, Inter
percutaneous transluminal angioplasty plus stent.
aNumbers represent only patients with a single ICD-9 procedure code, and
bMeans compared using Tukey’s Range Test (significance level.05); prop
q statistic q[.05] critical value).threat (25,575 to 13,762; P  .01). ABF procedures $ecreased by 38% for claudication (3184 to 1967; P .01),
hereas for limb threat they decreased 43% (1646 to 934;
 .01).
Costs. Average costs per case involving PTA  S pro-
edures for claudication rose from $8670 $5125 in 2001
o $14,084 9922 in 2007 (62.5% increase; P .01), and
ose similarly for limb threat from $13,903  $12,173 to
23,196  $27,640 (66.8% increase; P  .01; Fig 2). For
PG, average costs for claudication rose from $9322 
ic disease undergoing intervention in the nationwide
al bypass
Aortofemoral
bypass
Aortofemoral
bypass &
PTA
Peripheral
bypass & PTA
(%) (n) (%) (n) (%) (n) (%)
49.7 36,307 6.4 1337 0.2 26,823 4.8
66.5 4926 8.2 183 0.3 3301 5.5
64.5 4949 8.5 106 0.2 3014 5.2
60.5 4552 7.5 180 0.3 2999 4.9
60.0 4532 7.7 126 0.2 2943 5.0
53.8 4021 7.3 132 0.2 2977 5.4
47.3 3602 6.2 151 0.3 2849 4.9
40.4 3391 5.4 110 0.2 2802 4.4
33.6 3378 4.6 178 0.2 3059 4.2
30.7 2956 3.9 171 0.2 2879 3.8
he nationwide inpatient sample with claudication, by
ofemoral
ypass
24,033)
Peripheral
bypass
(n  102,604) 2 Multiple comparison testb
(SD) (n) (SD) All
PTA vs
ABF
ABF vs
periph
P value
PTA vs
periph
0 0.24 67 0.11  .001  .001  .001  .001
(%) (n) (%) P value q  q (.05)
1 44.9 38,066 37.1 .001 Yes Yes Yes
1 100.0 76,507 100.0 .001 Yes Yes Yes
1 88.1 64,326 84.1
7 5.8 4343 9.6
3 6.1 7838 6.3
6 7.7 6494 6.3 .008 Yes Yes Yes
4 3.1 4024 3.9 .001 Yes Yes Yes
7 61.0 69,583 67.8 .001 Yes Yes Yes
2 2.4 3284 3.2 .001 Yes Yes Yes
7 16.2 27,127 26.4 .001 Yes Yes Yes
2 4.0 4103 4.0 .0528 Yes Yes Yes
7 33.4 25,979 25.3 .001 Yes Yes Yes
al Classification of Disease, 9th Revision; periph, peripheral; PTA  S,
des 5% of patients with multiple procedures.
s compared using Multiple Comparison Test of Proportions (significance iflerot
ipher
n)
,021
,020
,591
,850
,197
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October 20111024 Sachs et althreat costs rose from $16,795  $14,692 to $22,910 
$19,916 (36% increase; P  .01). For claudication, the
average costs for PTA S were higher than those for BPG
beginning in 2003, whereas for limb threat, the costs
became higher for PTA  S over BPG in 2007. When
evaluating the individual limb threat indications, costs were
Table II. B, Demographics and comorbidities of patientsa
intervention: 1999-2007
Nationwide inpatient
sample (1999-2007)
Total
(n  298,911)
PTA  S
(n  89,776)
Ao
(n
Demographics (n) (SD) (n) (SD) (n
Mean age 72 0.11 73 0.2 6
(n) (%) (n) (%) (n
Female gender 131,958 46.5 45,247 50.4 561
Race 211,011 100.0 66,016 100.0 896
White 155,760 73.8 47,789 72.4 715
Black 33,406 15.8 10,278 15.6 107
Other 21,845 10.4 7949 12.0 73
Comorbidities
CHF 53,670 18.9 17,816 19.9 157
Valvular disease 20,358 7.2 6609 7.4 64
Hypertension 194,778 68.6 62,798 70.0 722
Renal failure 46,150 16.3 19,836 22.1 57
Diabetes 90,197 31.8 29,555 33.4 244
Obesity 8390 3.0 2890 3.2 37
ABF, Aortofemoral bypass; CHF, congestive heart failure; ICD-9, Inter
percutaneous transluminal angioplasty plus stent.
aNumbers represent only patients with a single ICD-9 procedure code, and
bMeans compared using Tukey’s Range Test (significance level .05); Prop
q statistic q[.05] critical value).
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01). Costs for rest pain rose 85% for PTA S and 37% for
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Volume 54, Number 4 Sachs et al 1025between 2001 and 2007 (P .01). Rest pain accounted for
11% ($312 million), and increased 432%. Ulcers accounted
for 18% ($534 million), increasing 383%. Gangrene ac-
counted for 26% ($766 million) and increased 359% (all
P  .01; Fig 4, A).
Costs for BPG over the same time period were $3.6
billion. Of that, 23% was associated with claudication
($800 million), which remained stable in costs per year
despite a 26% decrease in volume of procedures performed
over the 7-year period (P .063). Rest pain accounted for
17% of total BPG costs ($591 million), and decreased
minimally, by 1.4% (P  .048). Ulcers accounted for 21%
of total BPG costs ($753 million) and decreased 26% (P 
.01). Gangrene accounted for 37% of total BPG costs ($1.3
billion) and decreased 29% (P  .01; Fig 4, B). Last, total
costs for ABF were $570 million. Claudication accounted
for 60% ($340 million), rest pain accounted for 20% ($115
million), ulcers accounted for 8% ($50 million), and gan-
grene accounted for 10% ($68 million; Fig 4, C).
New Jersey state inpatient and ambulatory data-
bases. Between the years 2005 and 2007, in the New
Jersey inpatient database (n 4736; 100% sample), by our
criteria, there were 2882 patients (61%) who received
PTA S, 1521 patients (32%) who received BPG, and only
117 patients (2.5%) who received ABF. The remaining
4.5% received more than one procedure. Of claudicants
(n  2047), 73.8% patients (n  1510) received PTA  S,
20.9% patients (n  428) received BPG, and 2.5% patients
(n  52) received ABF.
When examining the New Jersey Ambulatory Surgery
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Fig 2. Mean costs (with SDs) of hospitalizations invol
graft (BPG) for claudication and limb threat: 2001-2007Database (100% sample), we identified 477 patients receiv- ing outpatient procedures, essentially all of which (n 
74; 99.4%) were PTA S. Of these patients, 341 (71.5%)
ad a diagnosis of claudication, and the remaining 136
atients (28.5%) had a diagnosis for limb threat. The mean
ssociated charges (cost-to-charge ratios are not available
or outpatient procedures) for these patients, the costs were
25,888 ( $12,026), and were similar between claudica-
ion for $26,085 ( $11,775) and limb threat for $25,224
 $12,665; Table III).
Outpatient charges for claudication, identified through
he New Jersey SASD, were approximately 8.2% of the total
npatient charges for the New Jersey SID (Table IV),
hereas for limb threat these charges were only the equiv-
lent of 1.3% of total inpatient charges.
Total annual costs. Between 2001 and 2007, costs
or all claudication procedures totaled $2.6 billion, and
osts per year increased by 111% from $265 to $559million
er year (Fig 5). Costs for all limb threat procedures totaled
4.9 billion, while costs per year increased 50% from $579
illion in 2001 to $870million in 2007 (P .01). Average
nflation of the U.S. dollar as identified by the Consumer
rice Index over this time period was 2.69% per year, and
otaled 17.1% between 2001 and 2007. When costs were
ompared using inflation-adjusted 2007 dollars, there was
o appreciable difference in statistical significance.
n-hospital mortality
In claudicants, the PTA  S group had similar, albeit
lightly lower rates of adjusted in-hospital mortality than
PG (0.2% vs 0.4%; odds ratio [OR], 0.48; 95% confidence
04 2005 2006 2007
Limbthreat: PTA Limbthreat: BPG 
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ionwide Inpatient Sample (NIS).20
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October 20111026 Sachs et althan ABF (1.5%; OR, 0.21; 95% CI, 0.13-0.32; P  .01)
on multivariable logistic regression (Fig 6). Similarly, for
limb threat the PTA S group had only slightly lower rates
of adjusted mortality than BPG (2.1% vs 2.6%; OR, 0.72;
95%CI, 0.63-8.83), but rates almost half that of ABF (2.1%
vs 4.1%; OR, 0.40; 95% CI, 0.32-0.51; P  .01).
In-hospital major amputation. In claudicants, am-
putation was rare, irrespective of the type of intervention
(PTA  S: 0.1%; BPG: 0.2%; ABF: 0.1%) and event rates
did not differ between groups (all P  .05). However,
when evaluating limb threat, PTA S showed significantly
higher rates of major amputation (7.0%) compared to BPG
(3.9%; OR, 1.67; 95% CI, 1.49-1.85; P  .01) and ABF
(3.0%; OR, 2.32; 95% CI, 1.79-3.03; P .01) on multivari-
B: Ulcer 
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Fig 3. A-C, Mean costs (with SDs) per hospitalization
plasty (PTA) or bypass graft (BPG) by indication: 2001-able logistic regression (Fig 7). Within limb threat, amputa- fion rates for rest pain, ulcer, and gangrene for PTA S were
.3%, 1.0%, 18.1%, respectively. For BPG, rest pain and ulcer
ates were similar to patients who had PTA  S (1.0% and
.7%) but were far lower with gangrene (9.1%; P .01).
When evaluating in-hospital mortality andmajor amputa-
ion as a single outcome of “death or amputation,” patients
ith PTA S had higher rates (8.51%) than did patients with
PG (8.5% vs 6.0%; P  .01) or patients with AFB (8.5% vs
.6%; P .01). The significance of these comparisons did not
ppreciably change on multivariable analysis.
Length of stay, admission, and discharge. Length of
tay was lowest in the PTA  S group (1.0 day  0.02
ays), followed by BPG (4.52 days  0.31 days), and ABF
5.88 days  0.05 days; P .01). The majority of patients
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Volume 54, Number 4 Sachs et al 1027clinic (87.8%), while the remaining patients arrived from
another hospital (9.0%), the emergency department
(2.1%), or other health facility/long-term care center
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ABF: 75.6%; P  .01).
DISCUSSION
Estimates of volume and outcomes for angioplasty-first
Table III. Mean chargesa associated with procedures in pa
New Jersey State inpatient and ambulatory (outpatient) su
Claudication
No.
Charg
Year Mean
Outpatient
2005 (n  166) 113 $22,038
2006 (n  134) 101 $24,500
2007 (n  177) 127 $30,666
Total (n  477) 341 $26,085
Inpatient
2005 (n  763) 415 $45,438
2006 (n  978) 493 $48,917
2007 (n  1141) 602 $53,990
Total (n  2882) 1510 $49,983
aCost-to-charge ratio data not available for outpatient procedures.
Table IV. Total charges associated with procedures in pat
New Jersey State inpatient and outpatient surgery database
Year
Claudication
Charges ($ millions)
Outpatient charge
% of inpatient chaOutpatient Inpatient Total
2005 $2.5 $29.3 $31.8 8.5
2006 $2.5 $36.3 $38.8 6.8
2007 $3.9 $42.4 $46.3 9.2
Total $8.9 $108.1 $117.0 8.2
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Fig 5. Annual national inpatient costs for hospitalizatio
(NIS). The increase in costs associated with inflation is aand bypass graft-first interventions in the literature are uften confounded by the combination of claudication with
imb threat.8,15,16 Our study seeks to address this problem
sing national data. Between the years 1999 and 2007,
TA S surpassed BPG for patients with both claudication
nd limb threat. For limb threat, the number of patients
ts identified as having claudication and limb threat in the
databases: 2005-2007
Limb threat
No.
Charges
SD Mean SD
$8830 53 $22,272 $8624
$8813 33 $28,021 $11,389
4,102 50 $26,761 $16,168
1,775 136 $25,224 $12,665
8,206 348 $86,957 $33,671
7,596 485 $99,187 $40,314
4,828 539 $96,847 $58,511
0,647 1372 $95,166 $45,778
identified as having claudication and limb threat in the
05-2007
Limb threat
Charges ($ millions)
Outpatient charges as a
% of inpatient chargesOutpatient Inpatient Total
$1.2 $88.4 $89.6 1.3
$0.9 $98.0 $99.0 0.9
$1.3 $104.5 $105.8 1.3
$3.4 $291.3 $294.7 1.2
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Volume 54, Number 4 Sachs et al 1029BPG by 40%, and for claudication that difference grew to a
nearly 2 to 1 margin. At the same time, total in-hospital
costs associated with PTA  S procedures between 2001
and 2007 increased almost fourfold, totaling approximately
$3 billion, half of which was due to claudication. Yet, mean
PTA  S costs for claudication were half that of limb
threat. While volume and costs for PTA  S quadrupled,
we saw minimal difference in mortality rates between
patients undergoing PTA  S and BPG. Moreover, we
found amputation rates were, in fact, higher with PTA 
S than with BPG.
It is interesting to note that the PTA S group had the
highest rates of comorbid renal failure. While only slightly
higher than the BPG group (12.6% vs 10.1%; P .001), it
was significant. It is possible that this negatively affected the
PTA  S group with regard to associated postoperative
outcomes of mortality and amputation. However, on mul-
tivariable logistic regression, all outcomes of mortality and
amputation were adjusted for gender, age, and comorbid
conditions of renal failure, congestive heart failure, diabe-
tes, hypertension, cardiac valvular disease, and chronic
0.2% 0.4%
1.5%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
%
 M
or
ta
lit
y
PTA
Claudication
Fig 6. In-hospital mortality for percutaneous translumi
bypass (ABF) by indication (claudication and limb threa
0.1% 0.2% 0.1%
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
noitacidualC
%
 M
aj
or
 A
m
pu
ta
tio
n
PTA
Fig 7. Major amputation during hospitalization with re
plasty [PTA], bypass graft [BPG], and aortofemoral bypobstructive pulmonary disease. Studies have shown in- tonsistent results with regard to management of claudi-
ation.10-14 Mazari et al10 showed no benefit between
TA  S and supervised exercise alone, although there
as a benefit when the two modalities were combined.
imilarly, Spronk et al,5 in a randomized control trial of
51 patients, showed no statistical benefit to endovascu-
ar revascularization over a supervised exercise program,
hich was favored in the generally accepted threshold
illingness-to-pay value. In an earlier study, Creasy et
l14 documented improved ankle-brachial pressure index
fter angioplasty, but without improved mean walking
istance, whereas the exercise group showed no im-
rovement in ankle-brachial pressure index, but had
tatistically significant improvement in mean walking
istance. An early randomized control trial using the
eterans Administration Cooperative Studies Program
y Wilson et al19 showed similar outcomes for angio-
lasty and bypass surgery in 255 patients, the majority of
hom had either claudication or rest pain. This was
onfirmed in a 4-year follow-up study by Wolf et al20 in
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benefit of PTA S over exercise for claudication remains
unanswered.
The recently released follow-up of the bypass vs
angioplasty in severe ischemia of the leg trial adds to the
similar debate between angioplasty and bypass graft for
limb threat. In their final report, the authors assert
no difference between angioplasty-first and bypass-first
groups up to 2 years, and an improved overall survival as
well as amputation-free survival in the bypass group
beyond 2 years. Their recommendations include bypass
for patients expected to live beyond 2 years unless oth-
erwise contraindicated. Since the majority of patients
who undergo these procedures are, indeed, expected to
survive beyond 2 years,21,22 this recommendation is
widely applicable. While intriguing, the highly selected
population which was randomized casts some doubt as
to the generalizability of their results. Furthermore, the
heterogeneity of endovascular techniques and the incor-
poration of prosthetic grafts make true comparisons
between cohorts difficult.23 More data to inform deci-
sion making should come with increased participation in
regional and national registries, incorporating anatomic
detail, patient comorbidities, and appropriate follow-up.
Potential changes to National Surgical Quality Improve-
ment Project in the future may address this need.
Our study is not a randomized control trial, and there-
fore is subject to confounding. By using multivariable
logistic regression in our analysis, we have attempted to
adjust for known confounders. However, selection bias,
patient preference, and anatomic differences cannot be
anticipated. Moreover, while we have attempted to adjust
for the use of multiple comparisons within particular hy-
potheses by statistical methods, there still remains a risk of
type I error beyond the 5% level owing to the multiple
outcomes we analyzed. The use of administrative discharge
data, as is found in the NIS, while providing a large volume
of patients, brings with it inherent limitations. Accuracy of
coding for comorbid conditions is variable,24,25 and often
selected by the data entry personnel, favoring diagnoses
with higher reimbursement rates.26
Due to the broad number of vascular procedures incor-
porated into ICD-9 codes, we were unable to effectively
separate aortoiliac angioplasty procedures from distal pro-
cedures, which would have made comparisons between the
PTA  S group and the BPG and ABF groups more
accurate. Also, upper extremity procedures are likely in-
cluded in our analysis; however, these represent a negligible
proportion of patients. We chose not to include patients
with a diagnosis of atherosclerosis unspecified in order to
better compare patients by indication for operation. How-
ever, the addition of these patients would undoubtedly
increase the associated costs presented here. We cannot be
certain whether the overall increase in claudication over
time is due to an increase in diagnosis or an increase in
interventions and it is more likely a combination of both.
We presume there are anatomic differences between
PTA  S and BPG groups which are not available in this Watabase. Current TransAtlantic Inter-Society Consensus
ecommendations which advocate for endovascular tech-
iques in shorter segment disease and open surgery in
onger or multiple occlusive diseases would lend bias to our
ndings against BPG. Furthermore, it is likely that a pro-
ortion of patients with PTA  S in our study were per-
ormed as salvage procedures before below knee amputa-
ion. Laterality is also absent, lending uncertainty as to
hether amputations were performed on the same limb as
he intervention. Our data only captures the in-hospital
vents, and fails to recognize the number of patients in both
roups who undergo salvage procedures, only to return at a
ater date to undergo amputation. Even so, the relatively
igh rate of amputations seen with PTA S in our study is
orrisome and merits further investigation.
Over 30% of angioplasty-first patients undergo reinter-
entions.9,18 To that end, it is highly likely that a consider-
ble proportion of the patients who receive PTA  S
dentified in our study are, in fact, multiple procedures on
he same patient. Therefore, costs for the individual patient
ith PTA S are likely higher than what we report, and the
ercentage of amputations in the PTA  S group would
lso potentially rise.
Additionally, we do not have national data on outpa-
ient procedures which limits our ability to truly identify the
dded volume and costs associated with angioplasty by the
mbulatory setting. Therefore, while our outpatient data
pply to New Jersey, we have no method to accurately
ccount for the proportion of outpatient procedures per-
ormed nationally. Based on the experience of New Jersey,
t is unlikely that outpatient procedures have a major effect
or limb threat. Future studies of costs of interventions for
laudication would need to account for outpatient proce-
ures.
Our study demonstrates that the average costs per
rocedure for both claudication and limb threat are increas-
ng, as are total costs for the treatment of these diseases.
oreover, costs per procedure for PTA  S are no longer
ower with PTA  S, and may, in fact, be even higher than
hat we report due to associated reinterventions. Proce-
ure volume is similarly rising for all indications, but partic-
larly for claudication, which is likely due to the increased use
f PTA  S. Better data are necessary in order to justify this
ncrease in both the use and the costs of PTA  S for
laudication. For limb threat, costs for PTA Shave also risen
o the level of BPG, but without a substantial benefit in
ortality, and with a far higher rate of amputation. We must
ave better selection criteria regarding the use of PTA  S,
PG, and exercise regimens for claudication and limb threat.
e would advocate for an increased use of prospective regis-
ries in order to provide consensus on the treatment options
hich exist for both claudication and limb threat.
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October 20111031.e1 Sachs et alAppendix. ICD-9 Diagnosis and Procedure Codes Used
ICD-9 Diagnosis Code
440.20
440.21
440.22
440.23
440.24
440.29
440.3
440.31
440.32
996.74
440.4
444.22
681.1
682.6
682.7
707.1
707.11
707.12
707.13
707.14
707.15
707.19
707.9
730.05
730.06
730.07
730.09
730.15
730.16
730.17
730.19
730.25
730.26
730.27
730.29
733.40-733.44, 733.49
440.9
429.2
443.81
443.9
250.7
040.0
785.4
447.1
447.2
ICD-9 Procedure Code
39.25
39.29
39.50
39.90Description
Atherosclerosis of the extremities, unspecified
Atherosclerosis of the extremities with intermittent claudication
Atherosclerosis of the extremities with rest pain
Atherosclerosis of the extremities with ulceration
Atherosclerosis of the extremities with gangrene
Atherosclerosis - Other
Atherosclerosis of unspecified graft
Atherosclerosis of autologous vein bypass graft
Atherosclerosis of nonautologous vein bypass graft
Other complications of internal vascular graft device or implant
Chronic total occlusion of artery of the extremities
Arterial embolism and thrombosis Lower extremity
Cellulitis and abscess of toe
Other cellulitis and abscess Leg, except foot
Other cellulitis and abscess Foot, except toes
Ulcer of lower limbs, except pressure ulcer - lower limb
Ulcer of lower limbs, except pressure ulcer - of thigh
Ulcer of lower limbs, except pressure ulcer - of calf
Ulcer of lower limbs, except pressure ulcer - of ankle
Ulcer of lower limbs, except pressure ulcer - of heel and midfoot
Ulcer of lower limbs, except pressure ulcer - of other part of foot
Ulcer of lower limbs, except pressure ulcer - of other part of lower limb
Chronic ulcer of unspecified site
Osteomyelitis - pelvic region and thigh
Osteomyelitis - lower leg
Osteomyelitis - ankle and foot
Osteomyelitis - multiple sites
Chronic osteomyelitis - pelvic region and thigh
Chronic osteomyelitis - lower leg
Chronic osteomyelitis - ankle and foot
Chronic osteomyelitis - multiple sites
Unspecified osteomyelitis - pelvic region and thigh
Unspecified osteomyelitis - lower leg
Unspecified osteomyelitis - ankle and foot
Unspecified osteomyelitis - multiple sites
Aseptic necrosis of bone - Lower Extremity
Generalized and unspecified atherosclerosis
Arteriosclerotic cardiovascular disease unspecified
Peripheral angiopathy in diseases classified elsewhere
Peripheral vascular disease, unspecified
Diabetes with peripheral circulatory disorders
Gas gangrene
Gangrene
Stricture of artery
Rupture of artery - Erosion, Fistula, Ulcer
Description
Aorta-iliac-femoral bypass
Other (peripheral) vascular shunt or bypass
Angioplasty or atherectomy of other non-coronary vessel(s)
